• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.

作者信息

Mei Junhao, Yu Haiyang, Qin Lihao, Jia Zhongzhi

机构信息

Junhao Mei, MD, Haiyang Yu, MD, Lihao Qin, MD, and Zhongzhi Jia, PhD, Department of Interventional and Vascular Surgery, No. 2 People's Hospital of Changzhou, Nanjing Medical University, Chang zhou, China.

出版信息

J Clin Oncol. 2022 Jun 1;40(16):1841. doi: 10.1200/JCO.21.02533. Epub 2022 Mar 22.

DOI:10.1200/JCO.21.02533
PMID:35316092
Abstract
摘要

相似文献

1
FOLFOX-HAIC for Unresectable Large Hepatocellular Carcinoma: The Effectiveness Has Yet to be Determined.
J Clin Oncol. 2022 Jun 1;40(16):1841. doi: 10.1200/JCO.21.02533. Epub 2022 Mar 22.
2
Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.奥沙利铂、氟尿嘧啶和亚叶酸钙肝动脉灌注与经动脉化疗栓塞治疗大肝细胞癌的随机III期试验
J Clin Oncol. 2022 Jan 10;40(2):150-160. doi: 10.1200/JCO.21.00608. Epub 2021 Oct 14.
3
Hepatic artery infusion chemotherapy using mFOLFOX versus transarterial chemoembolization for massive unresectable hepatocellular carcinoma: a prospective non-randomized study.使用改良FOLFOX方案的肝动脉灌注化疗与经动脉化疗栓塞术治疗巨大不可切除肝细胞癌的前瞻性非随机研究。
Chin J Cancer. 2017 Oct 23;36(1):83. doi: 10.1186/s40880-017-0251-2.
4
Intraarterial chemotherapy: another choice for unresectable advanced hepatocellular carcinoma?
J Chin Med Assoc. 2004 Dec;67(12):595-6.
5
Hepatic arterial infusion chemotherapy for patients with huge unresectable hepatocellular carcinoma.肝动脉灌注化疗治疗巨大不可切除肝细胞癌患者。
PLoS One. 2014 May 13;9(5):e92784. doi: 10.1371/journal.pone.0092784. eCollection 2014.
6
Chemoembolization alone vs combined chemoembolization and hepatic arterial infusion chemotherapy in inoperable hepatocellular carcinoma patients.不可切除肝细胞癌患者单纯化疗栓塞与化疗栓塞联合肝动脉灌注化疗的比较
World J Gastroenterol. 2015 Sep 28;21(36):10443-52. doi: 10.3748/wjg.v21.i36.10443.
7
ASO Author Reflections: Clinical Effectiveness and Safety of Transarterial Chemoembolization: Hepatic Artery Infusion Chemotherapy Plus Tyrosine Kinase Inhibitors With or Without Programmed Cell Death Protein-1 Inhibitors for Unresectable Hepatocellular Carcinoma-A Retrospective Study.ASO作者反思：经动脉化疗栓塞的临床疗效与安全性：肝动脉灌注化疗联合酪氨酸激酶抑制剂，联合或不联合程序性细胞死亡蛋白1抑制剂治疗不可切除肝细胞癌的回顾性研究
Ann Surg Oncol. 2024 Nov;31(12):7902-7903. doi: 10.1245/s10434-024-16049-3. Epub 2024 Aug 13.
8
Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.肝动脉灌注化疗与索拉非尼单药治疗晚期肝细胞癌患者的比较。
J Dig Dis. 2015 Sep;16(9):505-12. doi: 10.1111/1751-2980.12267.
9
A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.使用阿霉素进行高剂量肝动脉灌注化疗与经动脉化疗栓塞治疗难治性晚期肝细胞癌的对比研究。
Korean J Hepatol. 2010 Dec;16(4):355-61. doi: 10.3350/kjhep.2010.16.4.355.
10
Comparison of clinical outcome of hepatic arterial infusion chemotherapy and sorafenib for advanced hepatocellular carcinoma according to macrovascular invasion and transcatheter arterial chemoembolization refractory status.比较有大血管侵犯和经导管动脉化疗栓塞耐药状态的晚期肝细胞癌患者行肝动脉灌注化疗和索拉非尼治疗的临床结局。
J Gastroenterol Hepatol. 2018 Oct;33(10):1780-1786. doi: 10.1111/jgh.14152. Epub 2018 May 10.

引用本文的文献

1
Hepatic arterial infusion chemotherapy plus regorafenib compared with regorafenib alone as second-line therapy for advanced hepatocellular carcinoma: a randomised controlled trial protocol.肝动脉灌注化疗联合瑞戈非尼与单纯瑞戈非尼作为晚期肝细胞癌二线治疗的比较：一项随机对照试验方案
BMJ Open. 2024 Dec 7;14(12):e080805. doi: 10.1136/bmjopen-2023-080805.
2
Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities.精准医学时代晚期肝细胞癌的转化治疗：现状、挑战与机遇。
Cancer Sci. 2024 Jul;115(7):2159-2169. doi: 10.1111/cas.16194. Epub 2024 May 2.
3
Locoregional therapies for hepatocellular carcinoma: The current status and future perspectives.
局部区域治疗肝癌：现状与未来展望。
United European Gastroenterol J. 2024 Mar;12(2):226-239. doi: 10.1002/ueg2.12554. Epub 2024 Feb 19.
4
Hepatic Artery Infusion Chemotherapy Sequential Hepatic Artery Embolization Combined with Operation in the Treatment of Recurrent Massive Hepatocellular Carcinoma Achieved Pathological Complete Response: A Case Report.肝动脉灌注化疗序贯肝动脉栓塞联合手术治疗复发性巨块型肝细胞癌获病理完全缓解：1例报告
Pharmgenomics Pers Med. 2023 Nov 1;16:949-958. doi: 10.2147/PGPM.S426791. eCollection 2023.
5
Comparative effectiveness of interventional therapeutic modalities for unresectable hepatocellular carcinoma: A systematic review and network meta-analysis.不可切除肝细胞癌介入治疗方式的比较有效性：一项系统评价和网状Meta分析。
Oncol Lett. 2022 Aug 31;24(4):366. doi: 10.3892/ol.2022.13486. eCollection 2022 Oct.